卡双平治疗新诊断2型糖尿病患者的疗效及安全性研究
Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM
DOI: 10.12677/ACM.2020.109281, PDF,   
作者: 雷 莎, 周 筠*：同济大学附属同济医院内分泌代谢科，上海
关键词: 2型糖尿病；吡格列酮二甲双胍；血糖；糖化血红蛋白；T2DM； Pioglitazone/Metformin Fixed-Dose Combination； Glycemic； HbA1c
摘要: 目的：观察卡双平(吡格列酮二甲双胍)治疗新诊断2型糖尿病(type 2 diabetes mellitus, T2DM)患者的疗效及安全性。方法：选取35例新诊断的T2DM患者，观察卡双平治疗12周后糖化血红蛋白(hemoglobin A1c，HbA1c)及空腹血糖(fasting plasma glucose, FPG)的变化，明确药物的疗效及不良反应。结果：经过卡双平12周治疗后，新诊断的T2DM患者HbA1c及FPG水平明显下降(P < 0.05)，而且没有严重不良反应发生(P > 0.05)。结论：卡双平治疗新诊断的T2DM患者疗效确切，不良反应发生率低，可作为新诊断T2DM患者的治疗方案之一。
Abstract: Objective: To examine the efficacy and safety of pioglitazone/metformin fixed-dose combination therapy in a twice-daily regimen over 12 weeks treatment in newly diagnosed T2DM patients. Methods: 35 cases newly diagnosed T2DM patients were recruited. The changes of HbA1c, FPG and adverse events were evaluated at 12 weeks. Results: After 12 weeks treatment, HbA1c and FPG were significantly decreased compared with baseline. The pioglitazone/metformin fixed-dose combination was well tolerated with no unexpected findings in adverse events. Conclusions: The pioglitazone/metformin fixed-dose combination exhibits an excellent efficacy and safety for T2DM, which is a selection for those patients with newly diagnosed T2DM.
文章引用：雷莎, 周筠. 卡双平治疗新诊断2型糖尿病患者的疗效及安全性研究[J]. 临床医学进展, 2020, 10(9): 1869-1873. https://doi.org/10.12677/ACM.2020.109281

参考文献

[1] UK Prospective Diabetes Study Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). The Lancet, 352, 837-853. [Google Scholar] [CrossRef] 
[2] UK Prospective Diabetes Study Group (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet, 352, 854-865. [Google Scholar] [CrossRef] 
[3] Stratton, M.I. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412. [Google Scholar] [CrossRef] [PubMed]
[4] Holman, R.R., Paul, S.K., Angelyn Bethel, M., et al. (2008) 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 359, 1577-1589. [Google Scholar] [CrossRef] 
[5] Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J.W., Kang, S.C., Joh, H.-K., Kwon, H., Kim, J. and Park, D. (2017) Comparative Effectiveness of Oral Antidiabetic Drugs in Preventing Cardiovascular Mortality and Morbidity: A Network Meta-Analysis. PLoS ONE, 12, e0177646. [Google Scholar] [CrossRef] [PubMed]
[6] 朱大龙, 母义明, 翁建平, 等. 吡格列酮二甲双胍复方制剂临床应用专家建议[J]. 中国糖尿病杂志, 2017, 25(12): 1057-1063.
[7] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344.
[8] Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., et al. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 23, 1-87. [Google Scholar] [CrossRef] 
[9] Derosa, G., Maffioli, P., Salvadeo, S.A.T., et al. (2009) Direct Comparison among Oral Hypoglycemic Agents and Their Association with Insulin Resistance Evaluated by Euglycemic Hyperinsulinemic Clamp: The 60’s Study. Metabolism, 58, 1059-1066. [Google Scholar] [CrossRef] [PubMed]
[10] Perez, A., Zhao, Z., Jacks, R. and Spanheimer, R. (2009) Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy Compared with Pioglitazone and Metformin Monotherapy in Treating Patients with T2DM. Current Medical Research & Opinion, 25, 2915-2923. [Google Scholar] [CrossRef] [PubMed]
[11] Einhorn, D., Rendell, M., Rosenzweig, J., et al. (2000) Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study. Clinical Therapeutics, 22, 1395-1409. [Google Scholar] [CrossRef] 
[12] Perez, A., Jacks, R., Arora, V. and Spanheimer, R. (2010) Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared with Pioglitazone and Metformin Monotherapy in Patients with Type 2 Diabetes. Journal of Clinical Hypertension, 12, 973-982. [Google Scholar] [CrossRef] [PubMed]
[13] Andreas, P., Nikolaus, M., Georg, L., Langenfeld, M., Walcher, D., Konrad, T. and Forst, T. (2005) Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent from Glycemic Control: Results from the Pioneer Study. Journal of the American College of Cardiology, 45, 1925-1931. [Google Scholar] [CrossRef] [PubMed]
[14] Mazzone, T., Meyer, P.M., Feinstein, S.B., et al. (2006) Effect of Pioglitazone Compared with Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial. JAMA, 296, 2572-2581. [Google Scholar] [CrossRef] [PubMed]
[15] Chu, N.V., Kong, A.P.S., Kim, D.D., et al. (2002) Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients with Type 2 Diabetes. Diabetes Care, 25, 542-549. [Google Scholar] [CrossRef] [PubMed]

为你推荐